{
    "clinical_study": {
        "@rank": "137993", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "only DW330SR 45mg"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Experimental", 
                "description": "only DW1030 75mg"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Experimental", 
                "description": "DW330SR 45mg and DW1030 75mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate drugs interactions to compare pharmacokinetics in\n      groups of monotherapy DW330SR, monotherapy DW1030, and coadministration DW330SR and DW1030"
        }, 
        "brief_title": "Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Adult males aged 20~40 years at screening visit\n\n          -  Subjects with range of 19 kg/m2 ~ 27 kg/m2 as BMI measurements at screening visit\n\n          -  Subjects with BP range of below:\n\n             90 mmHg \u2264 Systolic BP \u2264 140 mmHg 50 mmHg \u2264 Diastolic BP \u2264 90mmHg\n\n          -  Subjects who voluntarily agreed with written consent that be able to understand the\n             objective, method of the study, the characteristics of investigational drug, and\n             comply with the reguirement of the study\n\n        Exclusion Criteria:\n\n          -  Subjects with clinically significant disease or history  such as Liver, kidney,\n             gastrointestinal, respiratory, musculoskeletal, endocrine, nervous psychiatric, blood\n             tumor system and cardiovascular. (In particular, bronchial asthma, severe hepatic,\n             renal failure, severe blood disorders, severe myasthenia gravis, cardiac dysfunction,\n             peptic ulcer, etc.)\n\n          -  Subjects with history of gastrointestinal disease (ex, Chrones dz, peptic ulcer, etc)\n             affect the absorption of Investigational drugs or history of surgery (except for a\n             simple appendectomy or hernia surgery)\n\n          -  Subjects with hypersensitivity reaction or clinically significant disease in drugs\n             (Aspirin, NSAID and antibiotics) including ingredient of DW330SR and DW1030 and Food"
            }, 
            "gender": "Male", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071381", 
            "org_study_id": "DW340-1001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A", 
                    "C"
                ], 
                "intervention_name": "DW330SR 45mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "B", 
                    "C"
                ], 
                "intervention_name": "DW1030 75mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 23, 2014", 
        "location": {
            "contact": {
                "email": "nohgj@amc.seoul.kr", 
                "last_name": "Gyu-Jeong Noh, M.D, Ph.D", 
                "phone": "+82-2-3010-4612"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center IRB"
            }, 
            "investigator": {
                "last_name": "Gyu-Jeong Noh, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "official_title": "A Randomized, Open Label, Single-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between DW330SR and DW1030 in Healthy Male Subjects", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Trans-OH as Main Metabolites of DW330SR, DW330SR, Cmax, AUClast of DW1030", 
            "time_frame": "-28 ~ -2day(screening), -1day, 1day, 2day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071381"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daewon Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}